Evidence map›Paper›PMID 33791704›Full record

ArticlebioRxiv : the preprint server for biology2021

Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants.

Yi-Nan Zhang, Jennifer Paynter, Cindy Sou, Tatiana Fourfouris, Ying Wang, Ciril Abraham, Timothy Ngo, Yi Zhang, Linling He, Jiang Zhu

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 8 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yi-Nan ZhangDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California 92037, USA.
Jennifer PaynterDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California 92037, USA.
Cindy SouDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California 92037, USA.
Tatiana FourfourisDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California 92037, USA.
Ying WangFels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, Pennsylvania 19140, USA.
Ciril AbrahamFels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, Pennsylvania 19140, USA.
Timothy NgoDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California 92037, USA.
Yi ZhangFels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, Pennsylvania 19140, USA.
Linling HeDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California 92037, USA.
Jiang ZhuDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California 92037, USA.
Scripps Research Institute · USTemple University · US

Funding

Structure-based design of coronavirus subunit vaccinesR01AI139092 · NIAID · NEW YORK BLOOD CENTER · PI DU, LANYING · 2018 to 2022
$4.2M
Rational design and evaluation of novel mRNA vaccines against MERS-CoVR01AI137472 · NIAID · NEW YORK BLOOD CENTER · PI DU, LANYING · 2018 to 2022
$4.1M
NIAID NIH HHS R01 AI137472NIAID NIH HHS R01 AI139092
6 · The paper itself

Abstract

Vaccines that induce potent neutralizing antibody (NAb) responses against emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are essential for combating the coronavirus disease 2019 (COVID-19) pandemic. We demonstrated that mouse plasma induced by self-assembling protein nanoparticles (SApNPs) that present 20 rationally designed S2GΔHR2 spikes of the ancestral Wuhan-Hu-1 strain can neutralize the B.1.1.7, B.1.351, P.1, and B.1.617 variants with the same potency. The adjuvant effect on vaccine-induced immunity was investigated by testing 16 formulations for the multilayered I3-01v9 SApNP. Using single-cell sorting, monoclonal antibodies (mAbs) with diverse neutralization breadth and potency were isolated from mice immunized with the receptor binding domain (RBD), S2GΔHR2 spike, and SApNP vaccines. The mechanism of vaccine-induced immunity was examined in mice. Compared with the soluble spike, the I3-01v9 SApNP showed 6-fold longer retention, 4-fold greater presentation on follicular dendritic cell dendrites, and 5-fold stronger germinal center reactions in lymph node follicles.

Indexed as

Ancestral strainbroadly neutralizing antibody (bNAb)coronavirus disease 2019 (COVID-19)self-assembling protein nanoparticle (SApNP)severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)vaccinevariant of concern (VOC)

Identifiers

PMID33791704
PMCPMC8010731
OpenAlexW3143923801

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.